Free Trial

Get While the Getting's Good, $7B AstraZeneca Launches

PIPELINE
AstraZeneca launches $7B over six tranches, drops the 3Y FRN. Chatter had been the pharmaceutical would issue two tranches over 30Y. No investor interest there.
  • Date $MM Issuer (Priced *, Launch #)
  • 05/25 $7B #AstraZeneca 7pt jumbo: $1.4B 2Y +20, $1.6B 3NC1 +40, $1.25B 5Y +45, $1.25B 7Y +55, $750M 10Y +70, $750M 30Y +80. For comparison: AZN issued $3B last year Aug 3: $1.2B +5Y +55, $1.3B 10Y +85, $500M 30Y +100.
  • 05/25 $2.75B Westpac $1.45B 5Y +40, $300M 5Y FRN SOFR+52, $1B 10Y +60
  • 05/25 $2.5B #Deutsche Bank $1B 3Y +60, $1.5B 11NC10 +148
  • 05/25 $2.3B #Hormel $950M 3NC1 +35, $750M 7Y +52, $600M 30Y +82
  • 05/25 $2B #Emirate of Abu Dhabi 7Y +45
  • 05/25 $500M *JAB Holdings 30Y +150
  • 05/25 $Benchmark AAC Tech 5Y +185a, 10Y +225s

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.